Evaluation of Insulin Dosage After the Addition of Tirzepatide Compared With Semaglutide or Dulaglutide in Patients With Type 2 Diabetes.

McKone DB, Duprey KS, Hall HM, Leonhard A, Schadler A, Naseman KW

Diabetes spectrum : a publication of the American Diabetes Association20 Feb 2025Cited by 2 (Europe PMC)

PMID40823594PMCIDPMC12357194DOI10.2337/ds24-0035PepBankPUB-40823594

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, tirzepatide was linked to greater weight loss than pooled dulaglutide and semaglutide at 6 months.
In plain wordsIn patients with diabetes, tirzepatide was linked to greater weight loss than pooled dulaglutide and semaglutide.
Peptide
Tirzepatide
Outcome
DecreaseWeight change at 6 months
Study
n = 135
Comparator
Pooled dulaglutide and semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Mean change in weight at 6 months
−8.5813 kg
tirzepatide group
Mean change in weight at 6 months
−3.4111 kg
combined dulaglutide and semaglutide group
Source sentences
Summary
Mean change in weight at 6 months was -8.5813 kg in the tirzepatide group and -3.4111 kg in the dulaglutide and semaglutide group (P <0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study using chart review of electronic health records to identify patients from a single academic medical center with type 2 diabetes who were initiated on tirzepatide, injectable semaglutide, or dulaglutide from 1 July 2021 to 31 May 2023 while on concomitant insulin…
Report a problemFND-4082359409
02HumanObservational studyEfficacy outcome
In patients with type 2 diabetes on insulin, tirzepatide was linked to unchanged median insulin requirements at 4-6 weeks.
In plain wordsIn patients with diabetes on insulin, tirzepatide was linked to unchanged insulin requirements at 4-6 weeks.
Peptide
Tirzepatide
Outcome
No significant changeInsulin requirement at 4-6 weeks
Study
n = 45
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Median percentage change in insulin requirement
0%
tirzepatide group, 4-6 weeks
Source sentences
Summary
The median percentage change in insulin requirement was 0% at 4-6 weeks (P = 0.286), -16.67% at 3 months (P P P = 0.013) for the tirzepatide group (n = 45)
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study using chart review of electronic health records to identify patients from a single academic medical center with type 2 diabetes who were initiated on tirzepatide, injectable semaglutide, or dulaglutide from 1 July 2021 to 31 May 2023 while on concomitant insulin…
Report a problemFND-4082359401
03HumanObservational studyEfficacy outcome
In patients with type 2 diabetes on insulin, tirzepatide was linked to a 16.67% reduction in median insulin requirements at 3 months.
In plain wordsIn patients with diabetes on insulin, tirzepatide was linked to lower insulin requirements at 3 months.
Peptide
Tirzepatide
Outcome
DecreaseInsulin requirement at 3 months
Study
n = 45
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Median percentage change in insulin requirement
−16.67%
tirzepatide group, 3 months
Source sentences
Summary
The median percentage change in insulin requirement was 0% at 4-6 weeks (P = 0.286), -16.67% at 3 months (P P P = 0.013) for the tirzepatide group (n = 45)
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study using chart review of electronic health records to identify patients from a single academic medical center with type 2 diabetes who were initiated on tirzepatide, injectable semaglutide, or dulaglutide from 1 July 2021 to 31 May 2023 while on concomitant insulin…
Report a problemFND-4082359402
04HumanObservational studyEfficacy outcome
In patients with type 2 diabetes on insulin, tirzepatide was linked to a 51.03% reduction in median insulin requirements at 6 months.
In plain wordsIn patients with diabetes on insulin, tirzepatide was linked to lower insulin requirements at 6 months.
Peptide
Tirzepatide
Outcome
DecreaseInsulin requirement at 6 months
Study
n = 45
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Median percentage change in insulin requirement
−51.03%
tirzepatide group, 6 months
Source sentences
Summary
The median percentage change in insulin requirement was 0% at 4-6 weeks (P = 0.286), -16.67% at 3 months (P P P = 0.013) for the tirzepatide group (n = 45)
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study using chart review of electronic health records to identify patients from a single academic medical center with type 2 diabetes who were initiated on tirzepatide, injectable semaglutide, or dulaglutide from 1 July 2021 to 31 May 2023 while on concomitant insulin…
Report a problemFND-4082359403
05HumanObservational studyEfficacy outcome
In patients with type 2 diabetes on insulin, tirzepatide was linked to a 58.33% reduction in median insulin requirements at 12 months.
In plain wordsIn patients with diabetes on insulin, tirzepatide was linked to lower insulin requirements at 12 months.
Peptide
Tirzepatide
Outcome
DecreaseInsulin requirement at 12 months
Study
n = 45
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Median percentage change in insulin requirement
−58.33%
tirzepatide group, 12 months
Source sentences
Summary
The median percentage change in insulin requirement was 0% at 4-6 weeks (P = 0.286), -16.67% at 3 months (P P P = 0.013) for the tirzepatide group (n = 45)
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study using chart review of electronic health records to identify patients from a single academic medical center with type 2 diabetes who were initiated on tirzepatide, injectable semaglutide, or dulaglutide from 1 July 2021 to 31 May 2023 while on concomitant insulin…
Report a problemFND-4082359404
06HumanObservational studySafety outcome
In patients with type 2 diabetes on insulin, decreased appetite was among the most common reported events with tirzepatide.
In plain wordsIn patients with diabetes on insulin, decreased appetite was among the most common reported events with tirzepatide.
Peptide
Tirzepatide
Outcome
Direction not reportedDecreased appetite
Study
n = 45
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
The most commonly reported adverse events in the tirzepatide group were decreased appetite, nausea, and vomiting.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study using chart review of electronic health records to identify patients from a single academic medical center with type 2 diabetes who were initiated on tirzepatide, injectable semaglutide, or dulaglutide from 1 July 2021 to 31 May 2023 while on concomitant insulin…
Report a problemFND-4082359412
07HumanObservational studySafety outcome
In patients with type 2 diabetes on insulin, nausea was among the most common reported events with tirzepatide.
In plain wordsIn patients with diabetes on insulin, nausea was among the most common reported events with tirzepatide.
Peptide
Tirzepatide
Outcome
Direction not reportedNausea
Study
n = 45
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
The most commonly reported adverse events in the tirzepatide group were decreased appetite, nausea, and vomiting.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study using chart review of electronic health records to identify patients from a single academic medical center with type 2 diabetes who were initiated on tirzepatide, injectable semaglutide, or dulaglutide from 1 July 2021 to 31 May 2023 while on concomitant insulin…
Report a problemFND-4082359413
08HumanObservational studySafety outcome
In patients with type 2 diabetes on insulin, vomiting was among the most common reported events with tirzepatide.
In plain wordsIn patients with diabetes on insulin, vomiting was among the most common reported events with tirzepatide.
Peptide
Tirzepatide
Outcome
Direction not reportedVomiting
Study
n = 45
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
The most commonly reported adverse events in the tirzepatide group were decreased appetite, nausea, and vomiting.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study using chart review of electronic health records to identify patients from a single academic medical center with type 2 diabetes who were initiated on tirzepatide, injectable semaglutide, or dulaglutide from 1 July 2021 to 31 May 2023 while on concomitant insulin…
Report a problemFND-4082359414

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with type 2 diabetes, pooled dulaglutide and semaglutide use was linked to less weight loss than tirzepatide.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide use was linked to less weight loss than tirzepatide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseWeight change at 6 months
Study
n = 135
Comparator
Tirzepatide
Outcome group
Body weight · Metabolic and weight
Measurements
Mean change in weight at 6 months
−8.5813 kg
tirzepatide group
Mean change in weight at 6 months
−3.4111 kg
combined dulaglutide and semaglutide group
Source sentences
Summary
Mean change in weight at 6 months was -8.5813 kg in the tirzepatide group and -3.4111 kg in the dulaglutide and semaglutide group (P <0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study using chart review of electronic health records to identify patients from a single academic medical center with type 2 diabetes who were initiated on tirzepatide, injectable semaglutide, or dulaglutide from 1 July 2021 to 31 May 2023 while on concomitant insulin…
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4082359410
10HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with type 2 diabetes, pooled dulaglutide and semaglutide use was linked to less weight loss than tirzepatide.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide use was linked to less weight loss than tirzepatide.
Peptide
Semaglutide
Outcome
IncreaseWeight change at 6 months
Study
n = 135
Comparator
Tirzepatide
Outcome group
Body weight · Metabolic and weight
Measurements
Mean change in weight at 6 months
−8.5813 kg
tirzepatide group
Mean change in weight at 6 months
−3.4111 kg
combined dulaglutide and semaglutide group
Source sentences
Summary
Mean change in weight at 6 months was -8.5813 kg in the tirzepatide group and -3.4111 kg in the dulaglutide and semaglutide group (P <0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study using chart review of electronic health records to identify patients from a single academic medical center with type 2 diabetes who were initiated on tirzepatide, injectable semaglutide, or dulaglutide from 1 July 2021 to 31 May 2023 while on concomitant insulin…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4082359411
11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with type 2 diabetes, pooled dulaglutide and semaglutide use was linked to unchanged median insulin requirements through 6 months.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide use was linked to unchanged insulin requirements through 6 months.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedInsulin requirement through 6 months
Study
n = 90
Outcome group
Glycemic control · Metabolic and weight
Measurements
Median percentage change in insulin requirement
0%
combined dulaglutide and semaglutide group, 4-6 weeks
Median percentage change in insulin requirement
0%
combined dulaglutide and semaglutide group, 3 months
Median percentage change in insulin requirement
0%
combined dulaglutide and semaglutide group, 6 months
Source sentences
Summary
and 0% at 4-6 weeks, 3 months, and 6 months and -12.50% at 12 months in the combined dulaglutide and semaglutide group (n = 90).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study using chart review of electronic health records to identify patients from a single academic medical center with type 2 diabetes who were initiated on tirzepatide, injectable semaglutide, or dulaglutide from 1 July 2021 to 31 May 2023 while on concomitant insulin…
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4082359405
12HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with type 2 diabetes, pooled dulaglutide and semaglutide use was linked to unchanged median insulin requirements through 6 months.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide use was linked to unchanged insulin requirements through 6 months.
Peptide
Semaglutide
Outcome
No significant changeInsulin requirement through 6 months
Study
n = 90
Outcome group
Glycemic control · Metabolic and weight
Measurements
Median percentage change in insulin requirement
0%
combined dulaglutide and semaglutide group, 4-6 weeks
Median percentage change in insulin requirement
0%
combined dulaglutide and semaglutide group, 3 months
Median percentage change in insulin requirement
0%
combined dulaglutide and semaglutide group, 6 months
Source sentences
Summary
and 0% at 4-6 weeks, 3 months, and 6 months and -12.50% at 12 months in the combined dulaglutide and semaglutide group (n = 90).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study using chart review of electronic health records to identify patients from a single academic medical center with type 2 diabetes who were initiated on tirzepatide, injectable semaglutide, or dulaglutide from 1 July 2021 to 31 May 2023 while on concomitant insulin…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4082359406
13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In patients with type 2 diabetes, pooled dulaglutide and semaglutide use was linked to a 12.50% reduction in insulin requirements at 12 months.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide use was linked to lower insulin requirements at 12 months.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseInsulin requirement at 12 months
Study
n = 90
Outcome group
Glycemic control · Metabolic and weight
Measurements
Median percentage change in insulin requirement
−12.5%
combined dulaglutide and semaglutide group, 12 months
Source sentences
Summary
and 0% at 4-6 weeks, 3 months, and 6 months and -12.50% at 12 months in the combined dulaglutide and semaglutide group (n = 90).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study using chart review of electronic health records to identify patients from a single academic medical center with type 2 diabetes who were initiated on tirzepatide, injectable semaglutide, or dulaglutide from 1 July 2021 to 31 May 2023 while on concomitant insulin…
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4082359407
14HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with type 2 diabetes, pooled dulaglutide and semaglutide use was linked to a 12.50% reduction in insulin requirements at 12 months.
In plain wordsIn patients with diabetes, pooled dulaglutide and semaglutide use was linked to lower insulin requirements at 12 months.
Peptide
Semaglutide
Outcome
DecreaseInsulin requirement at 12 months
Study
n = 90
Outcome group
Glycemic control · Metabolic and weight
Measurements
Median percentage change in insulin requirement
−12.5%
combined dulaglutide and semaglutide group, 12 months
Source sentences
Summary
and 0% at 4-6 weeks, 3 months, and 6 months and -12.50% at 12 months in the combined dulaglutide and semaglutide group (n = 90).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a retrospective cohort study using chart review of electronic health records to identify patients from a single academic medical center with type 2 diabetes who were initiated on tirzepatide, injectable semaglutide, or dulaglutide from 1 July 2021 to 31 May 2023 while on concomitant insulin…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4082359408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 3
21 Oct 2026, 18:59 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:07 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.